Basic and Clinical Andrology:新型可逆男式避孕凝胶

2017-04-09 佚名 煎蛋网

迄今为止,真正有效的男式避孕方式只有两种——避孕套、结扎(输精管切除)。但如今,局面即将发生改变。动物试验表明,一种新型男式避孕方式不仅有效性近乎 100%,而且能够完全逆转回来。它和结扎效果类似,但却无须切除输精管。Vasalgel 是一种聚合物凝胶,由加州非盈利组织帕萨默思基金会所研发。该基金会旨在寻找被制药产业所忽略的低成本避孕方式。Vasalgel 被注射进输精管内后,能够起到屏障作用,阻


迄今为止,真正有效的男式避孕方式只有两种——避孕套、结扎(输精管切除)。但如今,局面即将发生改变。动物试验表明,一种新型男式避孕方式不仅有效性近乎 100%,而且能够完全逆转回来。它和结扎效果类似,但却无须切除输精管。

Vasalgel 是一种聚合物凝胶,由加州非盈利组织帕萨默思基金会所研发。该基金会旨在寻找被制药产业所忽略的低成本避孕方式。Vasalgel 被注射进输精管内后,能够起到屏障作用,阻碍精子流出。通常,精子产自睾丸,然后通过输精管与其它分泌物混合形成精液。被凝胶阻隔后,精子要么嵌入凝胶内,要么被身体重新吸收。

你可能会心想,为什么人类直到 21 世纪才想出如此简单高效的方法——堵住输精管、而非切除输精管。那是因为这种方法对材料的要求非常高。材料必须呈惰性,易被注入细小输精管内,既要保持灵活性、又要固定在同一个地方。它既要最高效地过滤精子,又不能阻挡液体流出。Vasagel 成功做到了这一切。

去年,研究人员在 12 只兔子身上进行试验。注射一个月后,科学家没有发现任何精子细胞的迹象;在随后的 12 个月中,情况亦然。之后,研究人员在 16 只公恒河猴身上进行试验。它们和 9 只成熟母恒河猴相处了整个繁殖季节,却没有生出任何小猴子。其中 7 只恒河猴继续和母猴生活在一起达两年之久,没有任何后代。尽管恒河猴和兔子并非人类,但其生物相似性很高。

基金会希望在明年进行首次人体试验。之前曾有男式避孕剂研究卡在了人体试验环节——因为招不到人。但由于 Vasagel 已被证明完全可逆,因此可能比较容易招到男性志愿者。这回,研究人员将两种 Vasagel 注射到 7 只公兔子体内。14 个月后,他们用碳酸氢钠溶液 (俗称小苏打水) 中和、溶解凝胶结构,让精子重新自由通行。

由于凝胶材料会影响部分精子特性,因此科学家还需要进行更多研究,才能完全冲刷掉所有残留物。但总而言之,对于渴望半永久避孕的男性而言,Vasagel 或许能成为更好的选择。

原始出处:

Waller D, Bolick D, Lissner E, et al. Reversibility of Vasalgel? male contraceptive in a rabbit model. Basic and Clinical Andrology. 2017 Apr 5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779889, encodeId=883e1e798899b, content=<a href='/topic/show?id=28dc2499e8' target=_blank style='color:#2F92EE;'>#Androl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2499, encryptionId=28dc2499e8, topicName=Androl)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 21 04:21:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460928, encodeId=010b1460928bb, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Tue Apr 11 03:21:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507622, encodeId=36c0150e622bd, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Apr 11 03:21:00 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
    2017-10-21 Smile2680
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779889, encodeId=883e1e798899b, content=<a href='/topic/show?id=28dc2499e8' target=_blank style='color:#2F92EE;'>#Androl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2499, encryptionId=28dc2499e8, topicName=Androl)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 21 04:21:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460928, encodeId=010b1460928bb, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Tue Apr 11 03:21:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507622, encodeId=36c0150e622bd, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Apr 11 03:21:00 CST 2017, time=2017-04-11, status=1, ipAttribution=)]
    2017-04-11 lishizhe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779889, encodeId=883e1e798899b, content=<a href='/topic/show?id=28dc2499e8' target=_blank style='color:#2F92EE;'>#Androl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2499, encryptionId=28dc2499e8, topicName=Androl)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Oct 21 04:21:00 CST 2017, time=2017-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460928, encodeId=010b1460928bb, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Tue Apr 11 03:21:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507622, encodeId=36c0150e622bd, content=<a href='/topic/show?id=8764484014' target=_blank style='color:#2F92EE;'>#clinical#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4840, encryptionId=8764484014, topicName=clinical)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Apr 11 03:21:00 CST 2017, time=2017-04-11, status=1, ipAttribution=)]